179 related articles for article (PubMed ID: 36699027)
21. Efficacy and safety of SGLT-2i in overweight/obese, non-diabetic individuals: a meta-analysis of randomized controlled trials.
Shi Y; Si Y; Fu R; Zhang M; Jiang K; Dai W; Shen J; Li X; Yuan Y
Endokrynol Pol; 2022; 73(1):71-80. PubMed ID: 35119088
[TBL] [Abstract][Full Text] [Related]
22. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Shi N; Shi Y; Xu J; Si Y; Yang T; Zhang M; Ng DM; Li X; Xie F
Front Public Health; 2021; 9():668368. PubMed ID: 34164370
[No Abstract] [Full Text] [Related]
23. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus.
Lee SE; Nam H; Choi HS; Kim H; Kyoung DS; Kim KA
Diabetes Metab J; 2022 Jul; 46(4):567-577. PubMed ID: 35130688
[TBL] [Abstract][Full Text] [Related]
24. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy and safety of sodium-glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Ma J; Lu J; Shen P; Zhao X; Zhu H
Ren Fail; 2023; 45(2):2222847. PubMed ID: 37724571
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
Shin H; Schneeweiss S; Glynn RJ; Patorno E
Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
[TBL] [Abstract][Full Text] [Related]
27. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
28. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression.
Permana H; Audi Yanto T; Ivan Hariyanto T
Diabetes Res Clin Pract; 2023 Jan; 195():110205. PubMed ID: 36502891
[TBL] [Abstract][Full Text] [Related]
29. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Tanenberg RJ; Sewell KA; Cummings DM
Diabetes Metab; 2018 Mar; 44(2):112-120. PubMed ID: 29477373
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
31. Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study.
Palmiero G; Cesaro A; Galiero R; Loffredo G; Caturano A; Vetrano E; Rinaldi L; Salvatore T; Ruggiero R; Rosaria Di Palo M; Sardu C; Marfella R; Limongelli G; Calabrò P; Carlo Sasso F
Diabetes Res Clin Pract; 2023 Jun; 200():110686. PubMed ID: 37100231
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure.
Kasperova BJ; Mraz M; Svoboda P; Hlavacek D; Kratochvilova H; Modos I; Vrzackova N; Ivak P; Janovska P; Kobets T; Mahrik J; Riecan M; Steiner Mrazova L; Stranecky V; Netuka I; Cajka T; Kuda O; Melenovsky V; Stemberkova Hubackova S; Haluzik M
Cardiovasc Diabetol; 2024 Jun; 23(1):223. PubMed ID: 38943140
[TBL] [Abstract][Full Text] [Related]
33. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
34. Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis.
Zhuo M; Li J; Buckley LF; Tummalapalli SL; Mount DB; Steele DJR; Lucier DJ; Mendu ML
Kidney360; 2022 Mar; 3(3):455-464. PubMed ID: 35582176
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
Khunti K; Kosiborod M; Kim DJ; Kohsaka S; Lam CSP; Goh SY; Chiang CE; Shaw JE; Cavender MA; Tangri N; Franch-Nadal J; Holl RW; Jørgensen ME; Norhammar A; Eriksson JG; Zaccardi F; Karasik A; Magliano DJ; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P;
Cardiovasc Diabetol; 2021 Jul; 20(1):159. PubMed ID: 34332558
[TBL] [Abstract][Full Text] [Related]
36. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.
Mishriky BM; Okunrintemi V; Jain S; Sewell KA; Powell JR; Cummings DM
Diabetes Metab; 2021 Feb; 47(1):101160. PubMed ID: 32439471
[TBL] [Abstract][Full Text] [Related]
37. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.
Xia W; Yu H; Lei X; Wen P
Medicine (Baltimore); 2024 Mar; 103(11):e37432. PubMed ID: 38489694
[TBL] [Abstract][Full Text] [Related]
38. Influence of Sodium-Glucose Cotransporter-2 Inhibitors on Plasma Adiponectin in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Wang Y; Xia N
Horm Metab Res; 2022 Dec; 54(12):833-844. PubMed ID: 36049756
[TBL] [Abstract][Full Text] [Related]
39. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy.
Szwejkowski BR; Gandy SJ; Rekhraj S; Houston JG; Lang CC; Morris AD; George J; Struthers AD
J Am Coll Cardiol; 2013 Dec; 62(24):2284-93. PubMed ID: 23994420
[TBL] [Abstract][Full Text] [Related]
40. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
Paul SK; Bhatt DL; Montvida O
Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
